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Tak1 is aMAPKKK that can be activated by growth factors and cytokines such as RANKL and BMPs and its
downstream pathways include NF-kB and JNK/p38 MAPKs. Tak1 is essential for mouse embryonic
development and plays critical roles in tissue homeostasis. Previous studies have shown that Tak1 is a
positive regulator of osteoclast maturation, yet its roles in bone growth and remodeling have not been
assessed, as mature osteoclast-specific Tak1 deletion with Cstk-Cre resulted in runtedness and postnatal
lethality. Here we generated osteoclast progenitor (monocyte)-specific Tak1 knockout mice and found that
thesemice shownormal bodyweight, limb size and fertility, and osteopetrosis with severity similar to that of
RANK or RANKL deficient mice. Mechanistically, Tak1 deficiency altered the signaling of NF-kB,
p38MAPK, and Smad1/5/8 and the expression of PU.1, MITF, c-Fos, and NFATc1, suggesting that Tak1
regulates osteoclast differentiation at multiple stages via multiple signaling pathways. Moreover, the Tak1
mutant mice showed defects in skull, articular cartilage, and mesenchymal stromal cells. Ex vivo Tak12/2
monocytes also showed enhanced ability in promoting osteogenic differentiation of mesenchymal stromal
cells. These findings indicate that Tak1 functions in osteoclastogenesis in a cell-autonomous manner and in
osteoblastogenesis and chondrogenesis in non-cell-autonomous manners.
B
one related diseases, in particular osteoporosis and osteoarthritis, affect hundreds of million people world-
wide1–3. Osteoporosis is caused by disruption of the balance between bone formation, which is carried out by
osteoblasts, and bone resorption, which is carried out by osteoclasts4. Under normal conditions, bone resorption
and formation are coupled at multiple levels, and coordination between these two events is essential for maintaining
proper bone mass and for preventing the development of metabolic bone diseases such as osteopetrosis and osteo-
porosis. For example, mesenchymal stem cells (MSC) and osteoblasts synthesize M-CSF, RANKL, and OPG to
regulate osteoclastogenesis5,6. Yet how bone resorption communicates with formation is not completely understood7.
Osteoclasts are large multinucleated cells that secrete matrix proteinases including Cathepsin K (encoded by
Cstk), Tartrate-resistant acid phosphatase (TRAP) into resorption pits to degrade collagens and other matrix
proteins3,8. Osteoclasts are derived from the hematopoietic monocyte lineage, which can give rise to macrophage
and neutrophils as well. Osteoclast differentiation frommonocyte is a multiple-step process that requires distinct
signaling molecules and transcription factors at various stages9,10. Transcription factor PU.1 plays a role in early
monocyte differentiation and stimulates the expression of macrophage colony-stimulating factor (M-CSF).
Deletion of PU.1 in mice results in a complete lack of macrophages and osteoclasts and causes osteopetrosis11.
M-CSF can bind to its receptor and stimulate proliferation of monocytes12,13. RANKL, which can be provided by
MSCs and osteoblasts, promotes monocyte differentiation into osteoclasts14. RANKL binds to RANK molecules
located onmonocyte surface, leading to Tak1 (TGFb-activated kinase 1, encoded byMap3k7) activation via Traf6
and Tab2/Tab3/Tak1 complexes15. Tak1 then activates the p38MAPK, JNK, and NF-kB pathways16, which
further activate transcription factors NF-kB, c-Fos, c-Jun, MITF, and NFATc1 to turn on the expression of genes
such as TRAP, Cstk, and Integrin b3 in osteoclasts. The importance of these molecules in osteoclasts was
demonstrated by the findings that mice deficient for RANKL or RANK lack osteoclasts and show severe osteo-
petrosis14, and mice deficient for c-Fos and naturally occurring Mitf mutant mice (mi/mi mouse) also show
osteopetrosis by halting osteoclast differentiation and/or fusion17,18.
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Tak1 is a MAPKKK that can be activated by cytokines, growth
factors, and T/B cell receptors19,20. TGFb and BMPs activate Tak1 via
Traf6, which further activatesMAPK pathways, thus constituting the
non-canonical signaling pathway of the TGFb superfamily mem-
bers21. In addition, Tak1 can be activated by DNA damage and was
shown to have tumor suppressor activity22–24. Tak1 is an essential
gene and conventional deletion of Tak1 leads to embryonic leth-
ality25. Studies of conditional knockout mouse models indicate that
Tak1 is an essential regulator of innate immunity, hematopoietic
stem cell survival, energy sensing, and homeostasis of liver, smooth
and cardiac muscles, and cartilage26–31.
Several groups reported that Tak1 is required for osteoclast sur-
vival and differentiation in vitro32,33. Tak1 has been ablated inmature
osteoclasts with Cstk-Cre and the mice are severely osteopetrotic,
very small and die soon after birth, making them not suitable for
study of bone remodeling. In addition, Tak1 has been ablated in
monocyte to study its function in macrophage and neutrophils, yet
bone phenotypes were not reported34. Here we generated LysM-Cre;
Tak1f/f mice, which are viable, and studied bone remodeling in the
adultmice. Our findings reveal a role for Tak1 not only in early to late
stages of osteoclast differentiation via a combination of p38MAPK,
Smad1, and NF-kB and related transcription factors, but also in
skull/calvaria growth, articular cartilage growth, and in coupling to
MSC cells. The drastic differences in body weight, bone parameters,
and survival among LysM-Cre; Tak1f/f mice, Cstk-Cre; Tak1f/f mice,
Rankl2/2 mice, and Rank2/2 mice strongly suggest that Cstk
must be expressed in other cell types in addition to osteoclasts, and
that the phenotypes of Cstk-Cre; Tak1f/f mice may be caused by
combination of defects in osteoclasts and non-osteoclast cells.
Similar concerns were also raised by another recent study35. Thus,
LysM-Cre; Tak1f/f micemight present an animalmodelmore suitable
than Cstk-Cre; Tak1f/f mice to study the function of Tak1 in bone
remodeling.
Methods
Generation of conditional knockout of Tak1 in osteoclast precursors. The Tak1f/f
mice were generated in Michael D. Schneider’s lab at National Heart and Lung
Institute, Imperial College London United Kingdom30. The LysozymeM-Cre (LysM-
Cre) mice were purchase from The Jackson Laboratories. Genomic DNA was
extracted from mice tails and was used for genotyping. Two-month-old male mice
were used for bone histomorphometry experiments. All mice were housed in a
pathogen-free facility. Animal experimentation in this study was carried out in
accordance with recommendations in the National Research Council Guide for Care
and Use of Laboratory Animals, with the protocols approved by the Institutional
Animal Care and Use Committee of Shanghai, China [SYXK (SH) 2011–0112].
Radiographic imaging. The mice were anesthetized by intraperitoneal injection of
0.375 mg/kg tribromoethanol dissolved in 2-methyl-2-butanol. The mice were then
positioned properly and the radiographs of whole mouse were taken using Faxitron
(MX-20 Specimen Radiography System) for qualitative evaluation. The X-ray images
of the mutant and control mice of the same age and same gender were compared.
Villanueva-goldner’s trichrome staining of skull bone sections. Two-month-old
mice were euthanized and mouse heads were scalded in hot tap water for 30 sec. The
skin was carefully peeled off with forceps. Then the specimens were washed with PBS
and fixed in 4% paraformaldehyde (PFA) for 24 hrs, which were put into decalcifying
solution (15% EDTA) for 45 days until the bone was soft. The skull was then
dehydrated twice with 70% ethanol for 20 min each, twice with 95% ethanol for
30 min each, and twice with 100% ethanol for 30 min each, followed by twice in
xylene for 1 5 min each, in xylene/paraffin for 60 min at 58uC, three times in paraffin
for 60 min each at 60uC, and then embedded with paraffin. The bone was sectioned at
5 mm, which was stained using Villanueva-goldner’s one step trichrome method.
Bone histomorphometry. Bone histomorphometry analysis was carried out
following a protocol that has been previously described36,37. Briefly, seven days before
the mice were sacrificed for histomorphometry analysis, calcein was subcutaneously
injected at 0.2 mg/20 g body weight. One day before sacrificed, calcein was injected
again. The femurs were removed and fixed in 4% PFA overnight and then stored in
70% alcohol for future experiments. The bones were dehydrated in 95% ethanol
overnight, 100% ethanol for 5 hrs, 100% ethanol again overnight, which were then
changed to acetone for 5 hrs, vacuumed for 30 min, transferred into xylene
overnight, and vacuumed for 30 min. The bones were then embedded with resin,
sliced and stained with Villanueva-goldner’s one step trichrome method. All bone-
specific parameters were measured and expressed in units following the guidelines
established by the American Society for Bone and Mineral Research
histomorphometry nomenclature committee using OsteoMeasure software
(OsteoMetrics Inc).
TRAP staining. Bone samples were decalcified for 4 weeks in 10%
Ethylenediaminetetraacetic acid (EDTA) which were changed every 2 days, and then
dehydrated in graded concentrations of alcohol from 70% to 100%. Following
dehydration, samples were dealcoholised in xylene for 5 hours before being
embedded in paraffin, which were cut into 5 mm sections. TRAP staining was carried
out using Acid Phosphatase, Leukocyte TRAP Kit (387A, Sigma-Aldrich, St. Louis,
USA) according to manufacturer’s protocol. The slices were counter-stained with
0.05% Methyl Green and mounted with neutral gum.
Measurement of bone resorption markers. Deoxypyridinoline in the urine was
determined to evaluate the bone resorption rate, following the procedure
recommended by MicroVue (Quidel), which was normalized to the urine levels of
creatine. The concentration of calcium and inorganic phosphorus in the serum were
determined using Calcium Liquicolor (Stanbio) and PHOS (FosunLong March
Medical Science Co., Ltd) respectively.
In vitro osteoclastogenesis and TRAP analysis.Mice bone marrow was flushed out
with aMEM medium from the femurs and tibias. To induced the osteoclast
differentiation, isolated bonemarrow cells were first cultured inaMEMmediumwith
10% FBS at 37uC for 24 hrs. The floating cells were collected and seeded into 96-well
plate at 1 3 106/well, and were cultured in the presence of 20 ng/ml M-CSF and
40 ng/ml RANKL in aMEMmediumwith 10% FBS. Themediumwas changed every
3 days. After 7 days the cells were fixed and stained for TRAP usingAcid Phosphatase,
Leukocyte TRAP Kit (Sigma) following the manufacturer’s protocol. Then we
quantitated TRAP positive multinucleated osteoclast ($3 nuclei).
Immunohistochemistry staining. Detection of fibroblasts with anti-FSP-1
antibodies was performed on paraffin sections of calvarial bones by
immunohistochemistry staining. Tissue sections were processed with an antigen
retrieval step before they were incubated with anti-FSP-1 antibodies (Abcam)
overnight at 4uC. These slides were then washed three times with PBS, incubated with
horseradish peroxidase-labeled anti-rabbit antibody for 30 min at 37uC. The
horseradish peroxidase was developed with diaminobenzidine tetrahydrochloride
and hydrogen peroxide in PBS. Control sections were incubated without primary
antibody.
Mesenchymal stromal cell colony forming unit assay and ALP staining. Colony
forming unit assay was carried out following a protocol that has been previously
described38. Bone marrow was flushed out with aMEM medium (without serum)
from the femurs and tibias and was collected in 50 ml falcon tube. Single cell culture
was made through repeated passage through 19-gauge needles, which was then
centrifuged for 3 min at 1000 rpm. The cells were resuspended in complete aMEM
and plated at 5 3 106 per well in 6-well plates at 37uC for 24 hrs. The floating cells
were discarded. Fresh complete aMEM medium was changed every 3 days. Seven
days later, the plates were washed with cold PBS, fixed with 4% PFA for 30 min,
washed with ddH2O twice, and stained with an ALP detection kit (Sigma). The
stained areas were measured using a densitometry system.
Co-culture of MSC and monocyte/osteoclast. Co-culture experiments were carried
out following a protocol that has been previously described39. Briefly, primary MSC
were plated at 5 3 104 per well in 24-well plates for 24 hrs. Upon confluency, freshly
bone marrow monocytes were then plated on top of the MSC cells and cultured for 5
more days. The plates were then fixed and stained for ALP.
Quantitative PCR. Cells were collected 3 days later after M-CSF and RANKL were
added to induce osteoclast differentiation and total RNA was isolated from the cells
with Trizol reagent (Invitrogen). Reverse transcription was performed using
Transcriptor First strand cDNA synthesis kit (Roche) with random anchored-
oligo(dT)18 primers. Real-time PCRs were performed using FS Universal SYBR
Green Master Premix (Roche). Quantification was normalized to the amounts of
endogenous GAPDH. The primers used for real-time PCR were: c-Fos, forward-
CTGGTGCAGCCCACTCTGGTC, reverse- CTTTCAGCAGATTGGCAATCTC;
NFATc1, forward- CTCGAAAGACAGCACTGGAGCAT, reverse-CGGCTGC-
CTTCCGTCTCATAG; TRAP, forward-GCTGGAAACCATGATCACCT, reverse-
GAGTTGCCACACAGCATCAC;Mitf forward-CCCTCTCACCTGTTGGAGTCA,
reverse-CCGTTTCTTCTGCGCTCATAC; Integrin b3, forward- TATGTGGTGG-
AAGAGCCTGAGTG, reverse-TCTTTATACAGCGGGTTGTTTGC; PU.1,
forward-GATGGAGAAGCTGATGGCTTGG, reverse-TTCTTCACCTCGCCT-
GTCTTGC; GAPDH, forward-CCACAGTCCATGCCATCAC, reverse-CATACC-
AGGAAATGAGCTTGAC.
Western blot analysis. Cells or spleen tissues were lysed with lysis buffer (200 mM
Tris–HCl (pH 7.5), 1.5 M NaCl, 10 mM EDTA, 25 mM sodium pyrophosphate,
10 mM glycerolphosphate, 10 mM sodium orythovanadate, 50 mM NaF, 1 mM
PMSF, 0.5% Triton, in combination with protein inhibitor cocktail). Twenty
micrograms of protein lysates of each sample was subjected to SDS-PAGE analysis
and transferred onto nitrocellulose membranes. Blots were incubated with the
specific primary antibodies overnight at 4uC. After being washed three times for
www.nature.com/scientificreports
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Figure 1 | LysM-Cre; Tak1f/f mice showed splenomegaly and skull overgrowth. (a) Western blot result showed that Tak1 was deleted in monocytes/
osteoclasts of LysM-Cre; Tak1f/f mice. Monocytes were isolated from LysM-Cre; Tak1f/f and control mice and were induced to differentiate into
osteoclasts by RANKL andM-CSF for 3 days. The cells were then harvested and cell lysates were analyzedwithWestern blot to determine the protein levels
of Tak1. For the full-length blots see Supplementary Figure S1. (b) LysM-Cre; Tak1f/f mice developed splenomegaly. Spleens were dissected out
from 2 month-old LysM-Cre; Tak1f/f and control mice. (c) The abnormal morphology of the skull of the adult LysM-Cre; Tak1f/f mice. (d) LysM-Cre;
Tak1f/f mice show enlarged skull bones. Pictures were taken from 2month-old LysM-Cre; Tak1f/f and control mice. d1, the frontal bone; d2, palatoschisis;
d3, occipital bone; d4, verge-interparietal bone; d5, verge-parietal bone; d6, temporal bone frontal bone. (e) Villanueva-goldner’s trichrome staining
of the calvarial bones of LysM-Cre; Tak1f/f and control mice. Calvarial bones were decalcified, embedded in paraffin, sectioned, and stained with
Villanueva-goldner’s trichrome staining. Images of 43, 103, and 403 were shown in upper, middle, and bottom panels respectively. Arrows indicate
bone marrow cavities. (f) LysM-Cre; Tak1f/f mouse calvarial bones showed an increase in the number of FSP-1 positive fibroblasts. The decalcified
calvarial bones were immunostained with anti-FSP-1 antibodies and detected with a DAB substrate kit.
www.nature.com/scientificreports
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15 min each with TBST (TBS 1 0.1% Tween 20), blots were incubated with
horseradish peroxidase-conjugated secondary antibody (Sigma) and visualized by
chemiluminescence (Protein Simple).
Data analysis. Statistical comparisons were performed using unpaired Student’s two
tailed t test, with p values, 0.05 considered statistically significant when compared to
controlmice. For bone histomorphometry analysis, 8mutant and 8 controlmice were
used. For ex vivo studies, 3 pairs of mice were used. For experiments like western blot
analysis, cells from several mice were pooled.
Results
Generation of monocyte-specific Tak1 knockout mouse. Due to
postnatal lethality of Cstk-Cre; Tak1f/f mice24, we attempted to ablate
Tak1 from osteoclast progenitor cells using the LysM-Cre mouse,
which has been used to delete genes of interest in monocytes,
macrophages, and granulocytes34,40, hoping to study Tak1 function
in bone remodeling in adult mice. Western blot analysis of
osteoclasts extracts confirmed that Tak1 was greatly reduced
(Fig. 1a and Supplementary Fig. S1). The mutant mice also showed
an enlarged spleen (Fig. 1b), as previously reported34. These results
suggest that Tak1 is deleted in the mouse line. Unlike Cstk-mediated
Tak1 knockout mice32, LysM-Cre; Tak1f/f mice were born at expected
Mendelian frequency and the pups and adult mice have similar body
weights as control littermates (Supplementary Fig. S2). They are
fertile and have limbs with similar length to those of control mice
(Supplementary Fig. S2). Based on the fact that Rank2/2 mice and
Rankl2/2 mice, which have almost no osteoclasts, appear only
slightly smaller and do not show postnatal lethality14,41, our results
imply that Cstk might be expressed in osteoclasts as well as non-
osteoclast cells, and that the runtedness and postnatal lethality of
Cstk-Cre; Tak1f/f mice might be a result of defects of non-
osteoclast cells. As such, LysM-Cre; Tak1f/f mice might present an
animal model more suitable to study the function of Tak1 in bone
growth and remodeling.
Skull and articular cartilage anomaly in monocyte-specific Tak1
knockoutmouse. Some of the mice (5 out of 20mice) showed visible
anomaly of the skull, which was not obvious in newborn mice, but
gradually showed up with age (Fig. 1c and Table 1). The mice with
heterozygous deletion of Tak1 did not show this skull phenotype.
Dissecting of the skull revealed that the frontal bone, palatoschisis,
occipital bone verge, interparietal bone, verge-parietal bone, and
temporal bone of adult knockout mice were much bigger than
those of control adult mice (Fig. 1d). The calvarial bone in the
mutant mice also looked bigger than that of the control mice
(Fig. 1e). Section of calvarial bones revealed an increase in
cellularity and a lack of bone marrow cavities in LysM-Cre; Tak1f/f
mice (Fig. 1e). Immunohistochemistry staining revealed that the
mutant calvarial bones showed an increase in cells positive for
fibroblast-specific protein-1 (FSP-1) (Fig. 1f), suggesting that
deletion of Tak1 in monocytes/osteoclasts facilitates the proliferation
of fibroblasts in calvarial bones.
In addition, section of the femurs revealed that the growth plates
appeared normal in LysM-Cre; Tak1f/f mice (Fig. 2a and 2b), yet the
articular cartilage in all LysM-Cre; Tak1f/f mice is thicker than that of
normal mice (Fig. 2a and 2c), suggesting that Tak1 in monocyte/
osteoclast might affect chondrocyte proliferation and/or differenti-
ation at the articular surface. The lack of alteration in growth plate
may be due to the fact that osteoclasts, which are present in meta-
physis and diaphysis in long bones, are separated from the prolifera-
tion zone of the growth plate by the chondrocyte hypertrophy zone
and the degeneration zone, whereas articular chondrocytes, which
are not organized into zone-structures like epiphysis, are in close
contact with osteoclasts in the bone end plate (Fig. 2d).
Osteopetrosis phenotypes of adult monocyte-specific Tak1
knockout mouse. To determine whether osteoclast-specific deletion
of Tak1 affects bone remodeling in vivo, we radiographically examined
2 month-old LysM-Cre; Tak1f/f and control littermates. It was obvious
that the mutant mice showed amodest increase in overall bonemineral
density (Fig. 3a), yet heterozygous deletion of Tak1did not show
this phenotype (data not shown). We then performed bone
histomorphometry analysis of 2-months old male LysM-Cre; Tak1f/f
and control mice. It was found that the bone mass was increased in the
Tak1 deficient mice, with an increase in BV/TV, trabecular area,
trabecular number, trabecular thickness, but a decrease in trabecular
separation (Fig. 3b–3f). Collectively, these data suggest that LysM-Cre;
Tak1f/f mice showed an osteopetrotic phenotype. However, the increase
in bone mass in LysM-Cre; Tak1f/f mice compared to control
littermates is much less than the increase in Cstk-Cre; Tak1f/f mice
(46% vs 400%), but is closer to the increase (about 100%) in bone
mass/density reported in Rankl2/2 mice14. Since monocyte-specific
Tak1 deletion will be passed on to osteoclasts, the bone phenotypes of
LysM-Cre; Tak1f/f mice in theory should be similar to, if not worse
than, Cstk-Cre; Tak1f/f mice. The drastic increase in bone mass
observed in neonatal Cstk-Cre; Tak1f/f mice may be related to the
extreme small bone size32.
Bone formation and resorption of monocyte-specific Tak1
knockout mouse. Increased bone mass could be caused by
increased bone formation, decreased bone resorption, or both,
which are usually studied in 2 month-old mice. We then carried
out calcein double label experiments and found that the distance
between the two labels, which is a reflection of bone formation
rate, was not altered in the femurs of LysM-Cre; Tak1f/f mice
(Fig. 4a), nor was the calcein labels altered in the frontal bones or
the calvarial bones (Fig. 4b and 4c), which were enlarged in LysM-
Cre; Tak1f/f mice (Fig. 1d and 1e). Histomorphometric analysis
confirmed that Tak1 ablation in monocytes/osteoclasts did not
alter the bone formation rates or mineral apposition rates in the
femurs (Fig. 4d and 4e), nor did it affect bone formation rates
(147.56 6 15.88 for WT vs. 142.56 6 22.37 for the mutant) or
mineral apposition rates (1.131 6 0.112 for WT vs. 0.987 6 0.193
for the mutant) in the frontal bones. Moreover, the mutant mice did
not show any significant change in the number of osteoblasts per
bone surface in the femurs (Fig. 4f). These results suggest that
deletion of Tak1 in monocytes does not significantly alter bone
formation in 2 month-old mice. Thus, the increase in the size of
skull bones is not accompanied by thickening of the mineralized
bones. How Tak1 ablation in monocytes/osteoclasts affects the size
of skull bones warrants further investigation.
We then analyzed bone resorption markers and found that urine
deoxypyridinoline (DPD), a product of bone resorption, was
decreased in LysM-Cre; Tak1f/f mice (Fig. 4g), yet the concentration
of the inorganic phosphorus and calcium did not change much
(Fig. 4h and 4i). Note Rankl2/2 mice did not show much change
in serum levels of calcium and phosphorus either, although they
showed osteopetrosis14. Moreover, the number of osteoclasts was
significantly reduced in LysM-Cre; Tak1f/f mice (Fig. 4j). It is worth
tomention that the degrees of decrease in DPD levels and decrease in
the number of osteoclasts fall in the range of the increase in bone
volume in LysM-Cre; Tak1f/f mice, suggesting that osteopetrosis of
LysM-Cre; Tak1f/f mice is caused by decreased bone resorption due to
decreased osteoclast numbers.
Table 1 | The fraction of LysM-Cre; Tak1f/f mice that show abnor-
mal skull phenotypes
Genotype
Mice with skull defect Number of mice
Prevalence Age
Male Female Male Female
Tak1f/f 0 0 10 10 0 out of 20 2 month
LysM-cre;
Tak1f/f
3 2 10 10 5 out of 20 2 month
www.nature.com/scientificreports
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Figure 2 | LysM-Cre; Tak1f/f mice showed defects in articular cartilage. (a) The representative images of the distal end of femur bone that were taken
from 2 month-old LysM-Cre; Tak1f/f and control mice. The bones were decalcified, embedded in paraffin, sectioned, and stained with Villanueva-
goldner’s trichrome method. (b) LysM-Cre; Tak1f/f mice showed normal growth plate in femur bones. Dashed lines indicate the hypertrophied and
degenerated chondrocyte zones. (c) LysM-Cre; Tak1f/f mice showed thickened articular cartilage. The bones were the same as described in Fig. 2b. Bottom
panel: Quantitation data of the thickness of articular cartilage. N 5 8. **p, 0.01 when the value of mutant mice was compared to that of control mice.
(d) TRAP staining of femur bones shows that osteoclasts are present in the underchondral bone area of the articular cartilages (Left panel) and the
trabecular bone region underneath the growth plates (Right panel). Arrows indicate TRAP positive osteoclasts. Dashed lines indicate the hypertrophied
and degenerated chondrocyte zones.
www.nature.com/scientificreports
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Tak1 regulates osteoclast differentiation at multiple stages via
multiple signaling pathways. Previous studies suggested that Tak1
positively regulates osteoclast maturation32. To confirm these
findings, we isolated monocytes from adult LysM-Cre; Tak1f/f and
control mice, which were induced to differentiate into osteoclasts
with M-CSF and RANKL. Osteoclasts were then stained for TRAP,
a specific marker for osteoclasts. While mature multi-nuclear
osteoclasts ($3 nuclei) were successfully induced in the control
group, only a few of Tak12/2 osteoclasts were generated in the
same settings (Fig. 5a and 5b), yet the total number of TRAP
positive cells ($1 nucleus) was similar between WT and Tak12/2
cultures (data not shown), suggesting that the main difference is
osteoclast differentiation. Realtime PCR analysis showed that
osteoclast maturation marker TRAP and integrin b3 were
expressed at much reduced levels in the absence of Tak1 (Fig. 5c).
These results, together with the decrease in the number of osteoclasts
in vivo, suggest that Tak1 plays a critical role in osteoclastogenesis.
Osteoclast differentiation was controlled by several transcription
factors such as c-Fos and NF-kB. While freshly isolated monocytes
express undetectable levels of these transcription factors, the addi-
tion of RANKL and M-CSF greatly induced their expression, yet,
Tak1 deficient monocyte/osteoclast cultures showed a decrease in
PU.1, MITF, NFATc1, and c-Fos, with c-Fos expression being less
drastically reduced (Fig. 6a). Since PU.1 and MITF also act at the
committed myeloid precursor6,11, the results suggest that Tak1 may
play a role in early osteoclast differentiation stage before RANKL
exerts it action.
We then analyzed the signaling pathways that are involved in
osteoclast differentiation. We compared their activation in mono-
cyte/osteoclast cultures after induction of the differentiation pro-
gram. It was found that NF-kB molecules including p65 and p50
were down-regulated in the absence of Tak1 (Fig. 6b and
Supplementary Fig. S3), so were p38MAPK activation and Smad1/
5/8 activation, although to a much lesser extent (Fig. 6b and
Supplementary Fig. S3), suggesting that Tak1 is required for full
activation of these three pathways in monocytes/osteoclasts, as
shown in other cells42,43. Again, Tak1 deficiency decreased but not
abolished the activation of these signaling pathways, which is con-
sistent with the degree of decrease in osteoclast differentiation. Given
the well-established roles for p38MAPK-c-Fos and NF-kB in osteo-
clast differentiation, these results indicate that Tak1 might use both
p38MAPK and NF-kB signaling pathways to regulate osteoclast dif-
ferentiation. Recent studies also revealed an important role for BMP-
Smad1 signaling in osteoclastogenesis40,44. The decreased Smad1/5/8
activation may also contribute to altered osteoclast differentiation of
Tak12/2 monocytes. In addition, we also determined activation of
Figure 3 | LysM-Cre; Tak1f/f mice showed osteopetrosis phenotype. (a) Radiographic images of 2 month-old LysM-Cre; Tak1f/f and control mice. (b–f).
Trabecular bone parameters in 2 month-old LysM-Cre; Tak1f/f and control mice. BV/TV (b). Tb area (c). Tb thickness (d). Tb number (e). Tb separation
(f). The femurs were embedded with resin, sliced and stained with villauneva-goldner’s one step trichrome method. All bone-specific parameters were
measured and expressed in units following the guidelines established by the American Society for Bone and Mineral Research histomorphometry
nomenclature committee using OsteoMeasure software (OsteoMetrics Inc). N 5 8. *p, 0.05 when the value of mutant mice was compared to that of
control mice.
www.nature.com/scientificreports
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above mentioned signaling molecules in the homogenates of
spleen, which is much enlarged in the mutant mice (Fig. 1b),
and found that Tak1 deficiency led to a slight decrease in the
activation of p38MAPK and Smad1/5/8, but not NF-kB (Fig. 6c
and Supplementary Fig. S4). While previous studies have sug-
gested that Tak1 might have cell type-specific effects34, it is pos-
sible that the less obvious difference observed in the spleen is due
to the fact that Lysozyme positive monocytes constitute only a
small percentage of spleen mass and the Tak1 western blot results
is masked by other cells in the spleen.
Monocyte-specific deletion of Tak1 led to an increase in bone
marrow mesenchymal stromal cells. Although LysM-Cre; Tak1f/f
mice did not show a significant change in bone formation, we
found that the mutant mice showed an increase in mesenchymal
stromal cells, which are the progenitor cells for osteoblast,
Figure 4 | Bone formation and resorption parameters in LysM-Cre; Tak1f/f mice. (a) Calcein double labeling in femur of 2month-old LysM-Cre; Tak1f/f
and control mice. The mice were injected with Calcein twice with an interval of 7 days. The mice were sacrificed 1 day after the second injection.
The femur bones were embedded, sectioned, and the images were taken using a Nikon microscope. (b) Calcein double labeling in the frontal bones of
LysM-Cre; Tak1f/f and control mice. (c) Calcein double labeling in the calvarial bones of 2 month-old LysM-Cre; Tak1f/f and control mice. (d) Adult
LysM-Cre; Tak1f/f mice showed no change in bone formation rate (BFR). (e) Adult LysM-Cre; Tak1f/f mice showed no change in mineral apposition rate
(MAR). (f) Adult LysM-Cre; Tak1f/f mice showed no change in the number of osteoblasts. (g) LysM-Cre; Tak1f/f mice showed a decrease in urine DPD.
The ELISA assays were performed on urine collected from mutant and control mice. N 5 8. **p , 0.01 when the value of mutant mice was
compared to that of control mice. (h) LysM-Cre; Tak1f/f mice showed a normal level of serum Pi. (i) LysM-Cre; Tak1f/f mice showed a normal level of
serumCa21. (j) LysM-Cre; Tak1f/f mice showed a decrease in the osteoclast surface per bone surface. N5 8. **p, 0.01 when the value ofmutantmice was
compared to that of control mice.
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chondrocyte, and adipocyte4. We isolated bone marrow cells from
LysM-Cre; Tak1f/f and control littermates, lysed red blood cells, and
plated the same number of cells. After 7 days, the plates were stained
for ALP, amarker for osteoblasts. It was found that LysM-Cre; Tak1f/f
mice showed an increase in the number and the size of colony
forming units, a reflection of the number and proliferation of
osteoprogenitor cells (Fig. 7a). The correlation between defective
osteoclast differentiation and increased ALP positive CFU suggest
that Tak1 in osteoclasts might inhibit osteoblastogenesis. To test this,
we carried out a co-culture experiment of monocytes and MSC. The
same number of wild type MSC were plated and cultured overnight,
and the same number of bone marrow cells isolated from WT and
LysM-Cre; Tak1f/f mice were then added to the culture. These cells
were cultured for 5 more days and then stained for ALP. It was found
that Tak12/2 monocytes showed an increased ability to stimulate
MSCosteogenic differentiation (Fig. 7b), likely under the stimulatory
effects of BMP andWnt molecules present in the fetal bovine serum.
Collectively, these results revealed a role for osteoclast-expressed
Tak1 in regulating osteoblastogenesis. Note that the increase in the
number of MSC was not reflected in the number of osteoblasts and
bone formation rate in vivo.
Discussion
Osteoporosis, as well as osteosclerosis and osteopetrosis, arises when
the balance between bone formation and bone resorption is dis-
rupted2,3. Osteoclast-mediated bone resorption is a major target for
the development of drugs for osteoporosis prevention and therapy9.
So it is crucial to understand the signaling network that controls
osteoclastogenesis. Our study of the monocyte-specific Tak1 knock-
out mice confirmed an important role for Tak1 in osteoclastogenesis
and bone resorption in vivo. Yet the defects caused by Tak1 deletion
is much less than mature osteoclast-specific deletion of Tak1
mediated by Cstk-Cre, which are unexpectedly more severe than
those of Rankl2/2 or Rank2/2 mice41. Furthermore, while Cstk-
Cre; Tak1f/f mice show severe runtedness at birth and postnatal leth-
ality, the LysM-Cre; Tak1f/f mice appear normal in body weight and
limb size, fertility, and look normal from p1 to 12 month of age
except the skull phenotype. Given that Rankl2/2 and Rank2/2
mouse lines appear normal at birth and fertile and only develop
runtedness after weaning, it is possible that runtedness and postnatal
lethality of Cstk-Cre; Tak1f/f mice are not a direct result of osteoclast
defects. Instead, they are more likely to be caused by defects in other
cells/tissues that also express Cathepsin K, as previously reported35.
Our study also revealed that monocyte-specific deletion of Tak1
could lead to an increase in the sizes of the skull bones, although with
incomplete penetrance. The increase in the skull bone sizes is not
accompanied by an increase in the thickness of bones or bone forma-
tion rates. Instead, an increase in the number of fibroblasts was
observed in the calvarial bones. This phenotype is getting more obvi-
ous with age, suggesting that it is not a developmental defect, rather,
it is a problem arisen during growth. It has also been reported that
Tak1 is also involved in TGFBRII mutation-induced skull develop-
ment defects45. These findings, taken together, suggest that Tak1
might participate in the signaling events that control skull develop-
ment and growth. Yet, how Tak1 acts in osteoclasts to regulate skull
bone growth needs further investigation.
Analysis of LysM-Cre; Tak1f/f adult mice also revealed a role for
Tak1 in connecting osteoclastogenesis and osteoblastogenesis.
LysM-Cre; Tak1f/f adult mice showed an increase in ALP positive
colony forming units of bone marrow mesenchymal stromal cells,
suggesting that the defect in osteoclast differentiation might influ-
Figure 5 | LysM-Cre; Tak1f/f mice showed a defect in osteoclastogenesis. (a) LysM-Cre; Tak1f/f monocytes showed a reduction in differentiating into
TRAP positive osteoclasts. Bonemarrow suspension cells were cultured in the presence of RANKL andM-CSF for 7 days and were then stained for TRAP.
(b) Quantitation data of TRAP positive multinucleated osteoclast ($3). N 5 3. **p , 0.01 when the value of mutant cells was compared to that of
control cells. (c) LysM-Cre; Tak1f/f monocytes showed reduced expression of Integrin b3 and TRAP. Osteoclast cultures were collected three days after
addition of RANKL and M-CSF and total RNA was isolated from these cultures and realtime PCR was carried out to determine the mRNA levels of
Integrin b3 (left panel) and TRAP (right panel). N 5 3. **p , 0.01 when the value of mutant cells was compared to that of control cells.
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ence the differentiation potential of MSCs. Indeed, we found that
monocyte deficient for Tak1 showed an enhanced activity in pro-
moting MSC osteogenic differentiation in co-culture assays, likely
through growth factors/cytokines secreted bymonocytes/osteoclasts.
Surprisingly, we failed to observe an alteration in the number of
mature osteoblasts or bone formation rate in the 2 month-old
LysM-Cre; Tak1f/f mice. This discrepancy can be explained by that
the increasedMSC cells may serve as reserves and are not in an active
state, or that the effect of increased number of MSC cells may take
time to show up. In addition, we found that monocyte-specific dele-
tion of Tak1 led to an increase in the thickness of articular cartilage,
suggesting that osteoclasts might also communicate with MSC cells
at the articular surface to regulate chondrocyte differentiation. The
fact that monocyte-specific Tak1 deletion did not affect chondro-
cytes at the growth plate could be explained by that the hypertro-
phied chondrocyte zone and the degenerated chondrocyte zone
separate the proliferating chondrocytes from osteoclasts that are
present in the metaphysis. Thus, Tak1 presence in monocytes/osteo-
clasts appears to affect differentiation of the neighboring MSCs into
osteoblast or chondrocyte, suggesting that Tak1 is involved in com-
munication between osteoclast precursors and MSC, likely via syn-
thesizing and secreting cytokines and/or growth factors. Future
efforts will be needed to identify these cytokines and growth factors.
Tak1, as a downstream signalingmolecule of TGFb and BMPs, has
been shown to regulate chondrocyte proliferation and differentiation
in cell-autonomous manners, likely via downstream MAPK and
Figure 6 | Tak1 regulates osteoclast differentiation via multiple transcription factors and signaling pathways. (a) The reduced mRNA levels of various
transcription factors involved in osteoclast differentiation. Osteoclast cultures were collected three days after addition of RANKL and M-CSF and
total RNA was isolated from these cultures and realtime PCR was carried out to determine the mRNA levels of these transcription factors. N 5 3.
*p , 0.05, **p , 0.01 when the value of mutant cells was compared to that of control cells. (b) Reduced activation of Tak1 downstream signaling
pathways in Tak1 deficientmonocyte/osteoclast cultures. Osteoclast cultures were collected three days after addition of RANKL andM-CSF and cells were
harvested and Western blot was carried out to determine the levels of these activated signaling molecules. For the full-length blots see Supplementary
Figure S3. (c) Analysis of the signaling events in the spleen of LysM-Cre; Tak1f/f mice. Spleens were homogenized and the samples were analyzed by
western blot to determine the activation the signaling molecules. For the full-length blots see Supplementary Figure S4.
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Smad1/5/8 pathways42,43,46. In addition, mature osteoblast-specific
ablation of Tak1 also led to the development of cleidocranial dyspla-
sia, with a reduction in the parietal and frontal bones mineraliza-
tion47. This study and others’ show that Tak1 is also a positive
regulator of osteoclast differentiation and survival32. How does
Tak1 regulate osteoclast differentiation? The observation that PU.1
and MITF were markedly down-regulated in Tak12/2 monocytes/
osteoclasts suggests that Tak1 might play a role at early stage of
monocyte differentiation, before RANKL puts forth its action5,11.
Indeed, it has been reported that Tak1 plays an important role in
the differentiation of macrophages and neutrophils, two other pro-
genies of monocytes34. Furthermore, in response to RANKL, it seems
that Tak1 deficiency led to a decrease in NF-kB, p38MAPK, and
Smad1/5/8 activation. While NF-kB and p38 are well-established
promoter of osteoclast differentiation, a role for BMP-Smad1 path-
way in osteoclast differentiation needs to be further examined. Two
recent studies implicated that BMP-Smad1 signaling regulates osteo-
clast differentiation. Deletion of BMPRIA with Cstk-Cre (at day 4
after induction of differentiation) enhanced osteoclast differenti-
ation44, whereas LysM-Cre mediated ablation of BMPRII led to com-
promised differentiation40. We recently found that LysM-Cre
mediated ablation of BMPRIA resulted in enhanced osteoclast dif-
ferentiation (Li A. and Li B., unpublished results). Therefore it is
possible that decreased Smad1/5/8 activation acts as a balancing
mechanism to regulate osteoclast differentiation in LysM-Cre;
Tak1f/f mice. It is also possible that BMP-Smad1 signaling plays
different roles at various stages of osteoclast differentiation.
Mechanistically, BMP-Smad1 signaling might regulate osteoclast
differentiation by interacting with the NF-kB pathway. It has been
previously reported that Smad7, a target gene of BMP-Smad1 signal-
ing, interacts with Tab2/3 and thus inhibits the Tak1-NF-kB activa-
tion48. On the other hand, Tak1 was reported to interact with various
Smad molecules and this inhibits BMP-Smad1 signaling41,49,50.
In summary, this study revealed an important role for Tak1 in
monocyte/osteoclast differentiation, which might be mediated by
combined alterations of downstream signaling pathways, including
Smad1, NF-kB, and p38MAPK, and is quantitatively different from
the role revealed in mature osteoclasts. Moreover, Tak1 also plays a
role in communication from monocytes/osteoclasts to MSC and
regulatesMSC differentiation into osteoblasts or chondrocytes, likely
Figure 7 | Tak1 deficient monocytes/osteoclasts showed increased activity to promote osteoblastogenesis. (a) LysM-Cre; Tak1f/f mice showed an
increase in the number of ALP positive CFU. Bonemarrow cells were isolated and red blood cells were lysed. The cells were washed with PBS and counted.
5 3 106 cells were plated into each well of the 6 well plates and were cultured in a-MEM with 10% serum. The plates were stained for ALP after plated
for 7 days. Right panel: Quantitation data. N 5 5. **p , 0.01 when the value of mutant cells was compared to that of control cells. (b) LysM-Cre;
Tak1f/f monocytes showed a better activity to support MSC osteogenic differentiation in co-culture assays. Wild type MSC cells were plated and cultured
for 24 hrs. Freshly bonemarrowmonocytes isolated from LysM-Cre; Tak1f/f and control mice were plated on top of theMSC cultures, without RANKL or
M-CSF. After 5 days, the cells in suspensionwerewashed off and the adherentMSC cells were stained for ALP.N5 3. **p, 0.01when the value ofmutant
cells was compared to that of control cells.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 7158 | DOI: 10.1038/srep07158 10
via paracrine secretion of signaling molecules. By doing that, Tak1
regulates the growth of skull bones and articular cartilage.
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